Travere Therapeutics, Inc.
$40.29
▼
-3.12%
2026-04-21 09:57:01
travere.com
NGM: TVTX
Explore Travere Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.72 B
Current Price
$40.29
52W High / Low
$43.31 / $13.88
Stock P/E
—
Book Value
$1.26
Dividend Yield
—
ROCE
-14.11%
ROE
-57.8%
Face Value
—
EPS
$-0.57
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
497
Beta
0.87
Debt / Equity
286.28
Current Ratio
2.74
Quick Ratio
2.7
Forward P/E
6.97
Price / Sales
5.45
Enterprise Value
$2.68 B
EV / EBITDA
-1,286.52
EV / Revenue
5.46
Rating
Strong Buy
Target Price
$42.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
| 2. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 3. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 4. | SpyGlass Pharma, Inc. | $24.52 | — | $833.66 M | — | -38.64% | -67.7% | $32.44 / $20.15 | $-44.85 |
| 5. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 6. | Instil Bio, Inc. | $8.39 | — | $56.9 M | — | -26.15% | -50.39% | $42.79 / $5.67 | $16.79 |
| 7. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 129.69 M | 164.86 M | 114.45 M | 81.73 M | 74.79 M |
| Operating Profit | -32.43 M | 24.93 M | -12.65 M | -42.67 M | -59.33 M |
| Net Profit | 2.73 M | 25.71 M | -12.76 M | -41.23 M | -60.26 M |
| EPS in Rs | 0.03 | 0.28 | -0.14 | -0.45 | -0.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 490.73 M | 233.18 M | 145.24 M | 109.46 M |
| Operating Profit | -62.82 M | -321.39 M | -376.74 M | -319.81 M |
| Net Profit | -25.55 M | -321.55 M | -111.4 M | -278.48 M |
| EPS in Rs | -0.28 | -3.48 | -1.21 | -3.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 605.19 M | 594.12 M | 788.91 M | 672.59 M |
| Total Liabilities | 490.36 M | 535.05 M | 588.1 M | 629.73 M |
| Equity | 114.83 M | 59.08 M | 200.81 M | 42.85 M |
| Current Assets | 437.56 M | 416.7 M | 616.77 M | 486.44 M |
| Current Liabilities | 159.9 M | 200.75 M | 177.91 M | 142.16 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 37.78 M | -237.47 M | -280.02 M | -186.29 M |
| Investing CF | 27.89 M | 99.33 M | 55.78 M | -32.55 M |
| Financing CF | -33.47 M | 139.42 M | 218.75 M | 117.57 M |
| Free CF | -20.37 M | -338.69 M | -321.61 M | -214.66 M |
| Capex | -58.16 M | -101.21 M | -41.59 M | -28.37 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 60.55% | 32.69% | — | — |
| Earnings Growth % | -188.64% | 60% | — | — |
| Profit Margin % | -137.9% | -76.7% | -254.41% | — |
| Operating Margin % | -137.83% | -259.4% | -292.17% | — |
| Gross Margin % | 96.68% | 92.12% | 95.96% | — |
| EBITDA Margin % | -113.98% | -224.63% | -273.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.